Clinical Explorations of [⁶⁸Ga] Ga-FAPI-04 and [¹⁸F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Seminars in nuclear medicine Pub Date : 2024-11-02 DOI:10.1053/j.semnuclmed.2024.09.009

Yu Lin, Huaping Gao, Jiefu Zheng, Akram Al-Ibraheem, Pengcheng Hu, Hongcheng Shi

{"title":"Clinical Explorations of [68Ga] Ga-FAPI-04 and [18F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.","authors":"Yu Lin, Huaping Gao, Jiefu Zheng, Akram Al-Ibraheem, Pengcheng Hu, Hongcheng Shi","doi":"10.1053/j.semnuclmed.2024.09.009","DOIUrl":null,"url":null,"abstract":"Fibroblast activation protein inhibitor (FAPI) and [18F]fluorodeoxyglucose ([18F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols. PET/MR, with its multiparametric MR imaging, provides additional biological information for diagnosis. Studies have investigated the clinical feasibility of low-activity PET/MR imaging, yielding promising results. As there are still few institutions in the world that have experience with the advances provided by the use of total-body PET/CT and equipped with a PET/MR scanner, we have discussed the clinical explorations to reduce radiation exposure and optimize workflows for [68Ga]Ga-FAPI-04 and [18F]FDG dual-tracer PET/CT and PET/MR imaging. The review also provides potential new clinical explorations of [68Ga]Ga-FAPI-04 and [18F]FDG dual-tracer total-body PET/CT and PET/MR imaging, including dual-tracer dual-low-activity imaging.","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.semnuclmed.2024.09.009","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Fibroblast activation protein inhibitor (FAPI) and [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols. PET/MR, with its multiparametric MR imaging, provides additional biological information for diagnosis. Studies have investigated the clinical feasibility of low-activity PET/MR imaging, yielding promising results. As there are still few institutions in the world that have experience with the advances provided by the use of total-body PET/CT and equipped with a PET/MR scanner, we have discussed the clinical explorations to reduce radiation exposure and optimize workflows for [⁶⁸Ga]Ga-FAPI-04 and [¹⁸F]FDG dual-tracer PET/CT and PET/MR imaging. The review also provides potential new clinical explorations of [⁶⁸Ga]Ga-FAPI-04 and [¹⁸F]FDG dual-tracer total-body PET/CT and PET/MR imaging, including dual-tracer dual-low-activity imaging.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

68Ga] Ga-FAPI-04 和 [18F] FDG 双示踪剂全身 PET/CT 和 PET/MR 成像的临床探索。

成纤维细胞活化蛋白抑制剂（FAPI）和[18F]氟脱氧葡萄糖（[18F]FDG）可提供互补的生物学信息，近年来FAPI/FDG双示踪剂成像的临床应用日益增多。然而，FAPI/FDG 双示踪剂正电子发射断层扫描/计算机断层扫描（PET/CT）和 PET/磁共振（PET/MR）成像的最佳方案仍在研究中。全身 PET/CT 具有高灵敏度，可在示踪剂活性最小的情况下进行成像，并支持创建新的双示踪剂 PET/CT 成像方案。PET/MR 及其多参数磁共振成像为诊断提供了额外的生物信息。已有研究对低活性 PET/MR 成像的临床可行性进行了调查，结果令人鼓舞。由于世界上有经验使用全身 PET/CT 并配备 PET/MR 扫描仪的机构仍然很少，我们讨论了减少辐射暴露和优化 [68Ga]Ga-FAPI-04 和 [18F]FDG 双示踪 PET/CT 和 PET/MR 成像工作流程的临床探索。综述还提供了[68Ga]Ga-FAPI-04和[18F]FDG双示踪剂全身PET/CT和PET/MR成像（包括双示踪剂双低活度成像）的潜在新临床探索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.

期刊最新文献

Letter From the Editors. Clinical Explorations of [⁶⁸Ga] Ga-FAPI-04 and [¹⁸F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging. Emerging TSPO-PET Radiotracers for Imaging Neuroinflammation: A Critical Analysis. Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies. Update on PSMA-based Prostate Cancer Imaging.